Diabetes Care Drugs & Devices Market - 2025-2033
Diabetes Care Drugs & Devices Market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing with a CAGR of 8.30% during the forecast period 2026-2033.
The Diabetes Care Drugs & Devices Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Diabetes Care Drugs & Devices Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
Both primary and secondary data sources have been used in the global Diabetes Care Drugs & Devices Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Diabetes Care Drugs & Devices Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Diabetes Care Drugs & Devices Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
- Diabetes Devices*
- Blood Glucose Monitoring Devices
- Continuous Glucose Monitoring Devices
- Self-Monitoring Devices
- Blood Glucose Meters
- Testing Strips
- Lancets
- Insulin Delivery Devices
- Insulin Pumps
- Insulin Pens
- Insulin Syringes
- Others
- Diabetes Drugs
- Insulin
- Slow-acting Insulin
- Intermediate-acting Insulin
- Fast-acting Insulin
- Oral Anti-Diabetic Drugs
- Biguanides
- Sulfonylureas
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- Non-Insulin Injectable Drugs
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- Amylin Analogues
- Combination Drugs
- Others
- Type-1 Diabetes*
- Type-2 Diabetes
- Gestational Diabetes
- Prediabetes
- Hospitals*
- Specialty Clinics
- Homecare Settings
- Diagnostic Centers
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Diabetes Care Drugs & Devices Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Diabetes
3.1.1.2. Rising Advancements in Diabetes Devices
3.1.2. Restraints
3.1.2.1. High Cost of Diabetes Care Devices
3.1.2.2. Side Effects Associated with Diabetes Drugs
3.1.3. Opportunity
3.1.3.1. Advancements in Diabetes Wearables and Apps
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Latin America
4.5.5. Middle East & Africa
4.6. Porter’s Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
4.15. Pipeline Analysis
5. DIABETES CARE DRUGS & DEVICES MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Diabetes Devices*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Blood Glucose Monitoring Devices
5.2.3.1. Continuous Glucose Monitoring Devices
5.2.3.2. Self-Monitoring Devices
5.2.3.2.1. Blood Glucose Meters
5.2.3.2.2. Testing Strips
5.2.3.2.3. Lancets
5.2.4. Insulin Delivery Devices
5.2.4.1. Insulin Pumps
5.2.4.2. Insulin Pens
5.2.4.3. Insulin Syringes
5.2.4.4. Others
5.3. Diabetes Drugs
5.3.1. Insulin
5.3.1.1. Slow-acting Insulin
5.3.1.2. Intermediate-acting Insulin
5.3.1.3. Fast-acting Insulin
5.3.1.4. Others
5.3.2. Oral Anti-Diabetic Drugs
5.3.2.1. Biguanides
5.3.2.2. Sulfonylureas
5.3.2.3. Thiazolidinediones
5.3.2.4. Alpha-Glucosidase Inhibitors
5.3.2.5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
5.3.2.6. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
5.3.2.7. Others
5.3.3. Non-Insulin Injectable Drugs
5.3.3.1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
5.3.3.2. Amylin Analogues
5.3.4. Combination Drugs
5.3.5. Others
6. DIABETES CARE DRUGS & DEVICES MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Type-1 Diabetes*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Type-2 Diabetes
6.4. Gestational Diabetes
6.5. Prediabetes
7. DIABETES CARE DRUGS & DEVICES MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Homecare Settings
7.5. Diagnostic Centers
7.6. Others
8. DIABETES CARE DRUGS & DEVICES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd.*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.2. Abbott Laboratories
10.3. Medtronic plc
10.4. Terumo Corporation
10.5. B. Braun SE
10.6. Merck & Co., Inc.
10.7. Novo Nordisk A/S.
10.8. Eli Lilly and Company
10.9. Boehringer Ingelheim Pharmaceuticals, Inc.
10.10. Insulet Corporation LIST NOT EXHAUSTIVE
11. ASSUMPTION AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Diabetes
3.1.1.2. Rising Advancements in Diabetes Devices
3.1.2. Restraints
3.1.2.1. High Cost of Diabetes Care Devices
3.1.2.2. Side Effects Associated with Diabetes Drugs
3.1.3. Opportunity
3.1.3.1. Advancements in Diabetes Wearables and Apps
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Latin America
4.5.5. Middle East & Africa
4.6. Porter’s Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
4.15. Pipeline Analysis
5. DIABETES CARE DRUGS & DEVICES MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Diabetes Devices*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Blood Glucose Monitoring Devices
5.2.3.1. Continuous Glucose Monitoring Devices
5.2.3.2. Self-Monitoring Devices
5.2.3.2.1. Blood Glucose Meters
5.2.3.2.2. Testing Strips
5.2.3.2.3. Lancets
5.2.4. Insulin Delivery Devices
5.2.4.1. Insulin Pumps
5.2.4.2. Insulin Pens
5.2.4.3. Insulin Syringes
5.2.4.4. Others
5.3. Diabetes Drugs
5.3.1. Insulin
5.3.1.1. Slow-acting Insulin
5.3.1.2. Intermediate-acting Insulin
5.3.1.3. Fast-acting Insulin
5.3.1.4. Others
5.3.2. Oral Anti-Diabetic Drugs
5.3.2.1. Biguanides
5.3.2.2. Sulfonylureas
5.3.2.3. Thiazolidinediones
5.3.2.4. Alpha-Glucosidase Inhibitors
5.3.2.5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
5.3.2.6. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
5.3.2.7. Others
5.3.3. Non-Insulin Injectable Drugs
5.3.3.1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
5.3.3.2. Amylin Analogues
5.3.4. Combination Drugs
5.3.5. Others
6. DIABETES CARE DRUGS & DEVICES MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Type-1 Diabetes*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Type-2 Diabetes
6.4. Gestational Diabetes
6.5. Prediabetes
7. DIABETES CARE DRUGS & DEVICES MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Homecare Settings
7.5. Diagnostic Centers
7.6. Others
8. DIABETES CARE DRUGS & DEVICES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd.*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.2. Abbott Laboratories
10.3. Medtronic plc
10.4. Terumo Corporation
10.5. B. Braun SE
10.6. Merck & Co., Inc.
10.7. Novo Nordisk A/S.
10.8. Eli Lilly and Company
10.9. Boehringer Ingelheim Pharmaceuticals, Inc.
10.10. Insulet Corporation LIST NOT EXHAUSTIVE
11. ASSUMPTION AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
